Table 3.
Levels of urine biomarkers among different subgroups of patients with IC/BPS and the control patients.
| IC/ BPS | |||||||
|---|---|---|---|---|---|---|---|
| Urine Biomarkers @ | (A) GR ≤ 1, MBC ≥ 760 mL N = 44 |
(B) GR ≤ 1, MBC < 760 mL N = 46 |
(C) GR ≥ 2, MBC ≥ 760 mL N = 18 |
(D) GR ≥ 2, MBC < 760 mL N = 51 |
Control N = 28 |
p-Value * | Post Hoc Analysis |
| 8-OHdG | 29.56 ± 19.31 (0) | 30.12 ± 18.05 (0) | 42.97 ± 18.39 (0) | 42.13 ± 18.40 (0) | 18.33 ± 13.48 (0) | <0.001 | A, B, vs. D B, C, D vs. E |
| 8-isoprostane | 35.21 ± 26.55 (0) | 37.61 ± 32.18 (1) | 37.28 ± 25.57 (0) | 54.51 ± 34.28 (2) | 20.69 ± 21.15 (0) | <0.001 | A, B, C vs. D A, B, D vs. E |
| TAC | 1399.5 ± 1080.4 (0) | 1926.6 ± 1431.2 (1) | 962.8 ± 514.1 (0) | 1753.4 ± 1306.1 (5) | 1609.6 ± 1247.5 (6) | 0.003 | B vs. C C vs. D |
| MCP-1 | 209.3 ± 156.9 (1) | 263.7 ± 215.8(1) | 218.2 ± 186.4 (0) | 387.92 ± 355.17 (3) | 142.3 ± 93.02 (1) | <0.001 | A vs. D B, D vs. E |
| RANTES | 7.98 ± 8.02 (0) | 8.09 ± 5.67 (1) | 5.09 ± 5.02 (0) | 11.98 ± 10.01 (0) | 5.34 ± 4.56 (1) | <0.001 | C, E vs. D |
| CXCL 10 | 26.01 ± 34.24 (0) | 31.41 ± 43.18 (2) | 12.55 ± 22.84 (2) | 60.09 ± 72.69 (0) | 14.76 ± 18.63 (1) | <0.001 | A, C, E vs. D |
| Eotaxin | 7.30 ± 6.93 (0) | 8.73 ± 7.30 (1) | 5.85 ± 6.15 (1) | 10.20 ± 7.16 (2) | 4.88 ± 3.21 (1) | 0.004 | B, D vs. E |
| MIP-1β | 2.63 ± 2.16 (1) | 2.97 ± 1.87 (1) | 1.27 ± 0.91 (2) | 3.01 ± 2.17 (0) | 2.44 ± 1.59 (0) | 0.016 | A, B, D, E vs. C |
| IL-8 | 16.3 ± 18.24 (0) | 11.10 ± 11.13 (3) | 5.99 ± 3.96 (3) | 9.69 ± 10.37 (0) | 14.62 ± 24.13 (1) | 0.090 | |
Note: 8-OHdG, 8-hydroxy-2-deoxyguanosine; TAC, total antioxidant capacity; MCP-1, macrophage chemoattractant protein-1; RANTES, regulated upon activation, normal T cell expressed and presumably secreted; CXCL10, chemokine (C-X-C motif) ligand 10; MIP-1β, macrophage inflammatory protein 1β; GR, grade of glomerulation; MBC, maximal bladder capacity under anesthesia. (): indicates the number of outliers. *: p-values among different subgroups of IC/ BPS patients and control patients. @: units: all pg/mL, except ng/mL in 8-OhdG, and mmol/μL in TAC.